Purdue Pharma
201 Tresser Boulevard, Stamford, CT, 06901, United States
Overview
Purdue Pharma is a manufacturer of medications and consumer health products for healthcare professionals, patients, consumers, and caregivers. They sell public health initiative, prescription opioids, laxatives, antiseptics, and dietary supplement products. They combine science with care to provide medical products to patients and the healthcare system.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 6
Sector focus
- Biotechnology
- Health Care
- Pharmaceutical
Investment portfolio
- Harm Reduction Therapeutics
Led · Equity · Mar 2022
Harm Reduction Therapeutics (HRT) is a 501(c)(3) non-profit pharmaceutical company founded in 2017 in Stamford, Conn. The organization is developing a low-cost intranasal naloxone nasal spray intended for over-the-counter (OTC) sale to expand access and prevent opioid overdose deaths. HRT plans to file a New Drug Application for the naloxone nasal spray with the FDA in 2022. Since 2018 Purdue Pharma has supported HRT with financial contributions, technical expertise, and rights to data. The company recently received Bankruptcy Court approval for up to $11 million in additional funding from Purdue to advance development. HRT notes there is no guarantee the product will complete development or gain FDA approval, and if approved the OTC product would be offered at a substantially lower retail cost than current naloxone nasal spray products.
- Kolltan Pharmaceuticals
Participated · Series D · Mar 2014
Kolltan Pharmaceuticals is a New Haven, CT–based biopharmaceutical company focused on discovering and developing novel biologic agents designed to modulate receptor tyrosine kinases (RTKs). Its lead clinical-stage candidate, KTN3379, is a dual-mechanism monoclonal antibody that potently inhibits the ErbB3 RTK. The company intends to use the Series D proceeds to advance KTN3379 into Phase 2 clinical trials in cancer patients with various malignancies. Kolltan also plans to advance its preclinical candidates toward IND filing and clinical studies. Management is led by President and CEO Jerry McMahon, Ph.D., with Arthur Altschul, Jr. as Chairman. The company completed a $60M Series D to fund these development efforts. Kolltan Pharmaceuticals is developing a new generation of monoclonal antibody oncology therapeutics based on seminal discoveries from the laboratory of Dr. Joseph Schlessinger at the Yale School of Medicine. The company is advancing multiple therapeutic candidates in its pipeline and intends to use new funding to progress development. In January 2010 Kolltan closed a $10m Series B financing to support those efforts. The Series B consists of $8.5m in Series B convertible preferred stock and $1.5m that can be applied to a product development option or converted into Series B convertible preferred stock. Kolltan is based in New Haven, CT and previously completed a $40m Series A in which current investors also participated.